Does erythropoietin augment noise induced hearing loss?

Area of Science:

• Otolaryngology
• Neuroscience
• Pharmacology

Background:

• Noise-induced hearing loss (NIHL) involves glutamate, nitric oxide, and reactive oxygen species.
• Erythropoietin (EPO) shows neuroprotective effects in the central nervous system and retina.
• EPO's potential to prevent or reduce NIHL was hypothesized based on its known neuroprotective properties.

Purpose of the Study:

• To investigate the hypothesis that erythropoietin (EPO) prevents or reduces noise-induced hearing loss (NIHL).
• To evaluate EPO's efficacy across different administration routes, timing, and rodent species.
• To assess the impact of EPO on auditory function following noise exposure.

Main Methods:

• Three trials exposed guinea pigs and rats to specific wide-band noise (WBN) levels and durations.
• Erythropoietin (EPO) was administered via round window membrane, middle ear instillation, or intraperitoneal injection at various time points.
• Auditory function was assessed using oto-acoustic emissions and auditory brainstem responses before and after noise exposure.

Main Results:

• Noise exposure consistently induced hearing loss in all tested animals.
• EPO treatment did not prevent hearing loss; partial recovery was observed in some EPO-treated groups.
• Significantly worse hearing loss was observed in EPO-treated animals compared to controls in two of the three trials.

Conclusions:

• Contrary to expectations, erythropoietin (EPO) administration augmented noise-induced hearing loss in rodent models.
• Potential mechanisms include EPO-induced vasoconstriction affecting cochlear blood flow dynamics.
• Further research is needed to understand EPO's complex role in auditory system injury and repair.